The independent data management committee on the Intracept randomized controlled trial (RCT) has halted the study for efficacy at a prespecified interim analysis. The clinical trial found that for a specific kind of lower back pain, patients had a significant average reduction in pain at three months after treatment. The study found that treatment with the minimally invasive Intracept intraosseous nerve ablation system, which is from Minneapolis-based Relievant Medsystems Inc., was superior vs. non-surgical pain management. Read More
